RxDoctor Payments Data

Rajeev Pillai, MD

Interventional Cardiology · Chesapeake, VANPI 1093970071

Payments from drug & device makers

$3,810in general payments, 2019–2025

Across 75 payments — averaging $50.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Angiodynamics, Inc.$691
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$356
  • Abiomed$240
  • Inari Medical, Inc.$199
  • Boston Scientific$130
  • plus $772 from 20 others

What the payments were for

  • Consulting fees$40%
  • Travel & lodging$2,04354%
  • Food & beverage$1,76246%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,810 in reported general payments places this provider in the 35th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$49,488
Medicare patients
216
Services billed
475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$43,827
EntrestoSacubitril/Valsartan32$27,180
FarxigaDapagliflozin Propanediol29$21,394
Prasugrel Hcl13$2,029
Carvedilol52$212
Amiodarone Hcl16$204
Metoprolol Succinate21$181
ClopidogrelClopidogrel Bisulfate29$169
Atorvastatin Calcium22$158
Spironolactone43$130
Rosuvastatin Calcium15$118
Isosorbide Mononitrate ErIsosorbide Mononitrate11$58
Lisinopril14$50
Furosemide14$38
Metoprolol Tartrate26$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$43,82751 claims
NovartisEntresto$50$27,18032 claims
AstraZenecaFarxiga$12$21,39429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →